title: Induction of ERBB2 nuclear transport after radiation in breast cancer cells.
abstract: The ERBB2 nuclear transport in breast cancer cell lines after radiation and its possible role in radiation tolerance were observed. Confocal microscopy and Western blotting were applied to detect the nuclear ERBB2 expression after radiation in breast carcinomas cells. And the effects of Herceptin, AG825 and Cisplatin on the expression of nuclear ERBB2 were investigated. Survival fractions were also observed. After radiation, compared with control group, confocal microscopy and Western blot revealed that the expression of nuclear ERBB2 was increased in breast cancer cells time-dependently. Herceptin, and AG825 could significantly inhibit the radiation-induced nuclear ERBB2 expression, and decrease survival fractions. Cisplatin also induced the nuclear ERBB2 expression in breast cancer cells with high ERBB2 expression. It was concluded that radiation could induce ERBB2 nuclear transport, and nuclear ERBB2 may correlate with radiation resistance in breast cancer cells with high ERBB2 expression.
authors.affiliation: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. luobotongji@yahoo.com.cn
authors.forename: Bo
authors.initials: B
authors.lastname: Luo
authors.forename: Shiying
authors.initials: S
authors.lastname: Yu
authors.forename: Liang
authors.initials: L
authors.lastname: Zhuang
authors.forename: Shu
authors.initials: S
authors.lastname: Xia
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhao
authors.forename: Lei
authors.initials: L
authors.lastname: Rong
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000528:radiation effects; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D052160:Benzothiazoles / Q000494:pharmacology; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology; D005260:Female; D006801:Humans; D022022:Nuclear Pore / Q000378:metabolism*; D021381:Protein Transport / Q000528:radiation effects; D011836:Radiation Tolerance / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism* / Q000528:radiation effects; D000068878:Trastuzumab; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052160:Benzothiazoles; D002945:Cisplatin; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D020032:Tyrphostins; C098214:tyrphostin AG825; C508053:ERBB2 protein, human